STEM CELL NEW$ !!!
"Lt. Gov. Cruz Bustamante was in La Jolla Wednesday to appoint Dr.
Richard Murphy, the president and CEO of the Salk Institute, to the
state agency that will oversee $3 billion in funds allocated to the
stem cell research initiative."
This could fair well for Avanir (AVN) Pharmaceuticals http://www.avanir.com
( also based in San Diego and eligible for the
$3 billion CA funds) who have the patent for Stem Cell research using
Adult stem cells which is accepted by all political factions.
The Ultimate Stem Cell Patent & Investment
can be found in San Diego based Avanir (AVN) Pharmaceuticals
" ...unique approach ...difficult or even impossible to obtain by
"...methodology for generating fully human antibodies to a wide array
of infectious diseases... "
SAN DIEGO,/PRNewswire/ -- Xenerex Biosciences, a subsidiary of AVANIR
Pharmaceuticals (Amex: AVN), announced that it has licensed the
rights to a patent for grafting adult human stem cells into severe
combined immunodeficient (SCID) mice. The ability to engraft adult
human stem cells, which may respond to unique antigens with unique
antibodies, broadens the company's technological resources with yet
another important option in generating fully human monoclonal
"The addition of this exclusive method extends our technology
platform with another methodology for generating fully human
antibodies to a wide array of infectious diseases and human
proteins," said J. David Hansen, president and chief operating
officer of Xenerex Biosciences. "With the addition of this unique
approach we hope to generate B-cells and antibodies, that are
difficult or even impossible to obtain by other methods. We intend to
further develop this technology and are excited by both the synergies
and the new opportunities this patent presents in our pursuit of
research collaborations to maximize and commercialize our expertise
in antibody generation."
The patent, U.S. 5994617, "Engraftment of Immune-Deficient Mice With
Human Cells" was originally issued to John Dick, Ph.D. and Suzanne
Kamel-Reid, Ph.D. of The Hospital for Sick Children (HSC) in Toronto,
Canada. The patent allows for the engraftment of diverse sources of
adult human cells, including bone marrow, cord blood and liver cells.
These grafts have been found to be capable of differentiating into B-
cells, the cells responsible for antibody production.
Xenerex will be responsible for development of the technology under a
license agreement with HSC Research and Development Limited
Partnership and will pay a royalty to the partnership if products are
marketed utilizing this specific technology. Other terms of the
agreement were not disclosed.
The existing patented technology of Xenerex is focused on engrafting
mature human immune system cells into SCID mice and generating human
monoclonal antibodies from immunization of these cells in the mice.
The newly licensed technology gives Xenerex the capability to
generate a renewable pool of millions of human B-cells from the
engrafting of the adult human stem cells into SCID mice. The mice
provide an environment for these cells to multiply and differentiate
into human B-cells. These B-cells may then be stimulated to produce
totally human antibodies for a wide array of antigens using Xenerex's
AVN, Potential multi-billion dollar blockbuster drug in Phase 3 with
remarkable results, fantastic Anthrax Antibody, unique Cancer
Compound unlike anything ever seen before, IgE for allergies,Herpes
cream worlwide, unique Stem Cell patent, anti-cholestoral drug,
Xenerex completely human mABs!